The primary purpose for establishing this study is to have a comprehensive source of observational data that can be used to study stem cell HSC transplantation and outcomes at Weill Cornell Medical College.

The main purpose of the LeUprolide plus Cholinesterase Inhibition to reduce Neurological Decline in Alzheimer's (LUCINDA) study is to determine whether the medication Eligard (leuprolide acetate subcutaneous injection) may slow or prevent decline in thinking abilities and functioning in women with Alzheimer’s Disease (AD) who are also taking the medication donepezil (Aricept).

The goal of this study is to create a registry of patients with gastrointestinal malignancies. This registry will provide important information about the types of gastrointestinal cancers seen at the institution, their presentation, and course of disease. We plan to review, analyze pathological features, clinical features, and other parameters of digestive diseases as related to types of treatment, patterns of care, time to progression, and survival at NYPH-Weill Cornell Medical Center.

Why is the Sponsor conducting this study?

The study will look at patients with spontaneous intracranial hemorrhage while taking statins. The patient will then be randomized to continue or discontinue statin therapy to continue to treat the patient after the initial event.

The purpose of this study is to better identify and predict individuals at risk for Alzheimer's disease (AD) who are most likely to benefit from personalized, evidence-based interventions. Studies have shown that endocrine aging (menopause, perimenopause) increases Alzheimer’s disease risk specifically in women. Our goal is to unravel the biological mechanisms behind the increased risk by analyzing how various measures of brain function, biochemistry, laboratory values, and other risk factors may influence Alzheimer’s risk as women age.

The purpose of this study is to test whether active tasks completed on a personal smartphone are feasible as an approach to collecting data from patients with movement disorders. In particular, we are investigating whether it is a user-friendly interface for patients with movement disorders. The active tasks that participants will complete measure dexterity and speed, which are major components of the Unified Parkinson’s Disease Rating Scale and Movement Disorder Society Scales.

Effective treatment to prevent disability MS has been largely non-existent due to a poor understanding of the relevant pathophysiologic mechanisms. The purpose of the study is use novel PET and MRI techniques to study acute multiple sclerosis (MS) lesion. We will use a Magnetic Resonance Imaging (MRI) imaging sequence (programmed set of parameters and magnetic gradients) which will measure myelin and iron within lesions. Positron Emission Tomography (PET) is another test which may be more detailed information about factors causing damage within MS lesions. MRI is a test approved by FDA.

This study aims to determine if apixaban is superior to aspirin for prevention of stroke or hemorrhage or death in patients with recent intracerebral hemorrhage or atrial fibrillation.

Parkinson's disease affects 1 in 100 people over the age of 65, but the time between Parkinson's disease onset and diagnosis can be many months or years. Interestingly, pathological hallmarks of Parkinson's in the brain can also be seen in the neurons in the gut and symptoms like constipation often precede the onset of tremor and incoordination by many years. It is now believed that Parkinson's disease may begin in the gut, at least in some people.